Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)
Gary Lyman, MD, MPHIn September 2017, the US Food and Drug Administration (FDA) approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename. Although bevacizumab-awwb is the only biosimilar […] Read more
Liquid biopsies have also opened new perspectives in the field to which Blackhall has dedicated much of her research career. “I would like to use this award to highlight the […] Read more
Johan Vansteenkiste: A lifelong commitment to improving outcomes in thoracic oncology
Vansteenkiste leads the Respiratory Oncology Unit at University Hospitals Leuven, where he has been involved in approximately 300 lung cancer trials. He has served on the editorial boards of numerous […] Read more
Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team
Carolyn Vachani, RN, MSN+more
Lung cancer is one of the most common cancers worldwide, with more than 2 million people diagnosed each year.1 Advances in early detection and treatment have resulted in more people […] Read more
COVID-19 and Lung Cancer: A Call for Immediate Action
David R. Baldwin, MD, FRCPThe COVID-19 pandemic has had a devastating effect on lung cancer outcomes in the United Kingdom (UK). Fewer people have presented or have been referred for investigation, and those who […] Read more
A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC
Nobuyuki Takahashi, MD, PhD+more
Discovery of targetable genomic alterations, including mutations of EGFR, have resulted in improved survival for patients with non-small cell lung cancer (NSCLC).1 Although many patients experience robust responses to EGFR-targeted […] Read more
Mitigating Pain in Thoracic Surgery
Bryan V. Anderson, MCHS, PA-C+more
A middle-aged woman walks into the clinic using her right hand to hold her shirt away from her chest. “Even just my shirt brushing against my skin hurts,” she says […] Read more
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately
Hina Saeed, MD+more
Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5 Whereas upfront stereotactic […] Read more
New IASLC Grading System for Pulmonary Adenocarcinoma Proposed
Andre L. Moreira, MD, PhD+more
Tumor grading is an important component of a pathology report, as it has been traditionally used as a prognostic indicator. For many tumors, grading is also used to help with […] Read more
Brendon Stiles, MD
Formerly an associate professor of cardiothoracic surgery at Weill Cornell Medicine, Brendon Stiles, MD, is now Chief of Thoracic Surgery and Surgical Oncology and Associate Director of Surgical Services for […] Read more